Proliferation rate but not mismatch repair affects the long-term response of colon carcinoma cells to 5FU treatment

Cancer Letters

Volumn 320, Issue 1, 2012, Pages 56-64

  Choudhary, B ^a   Hanski, M L ^a   Zeitz, M ^a   Hanski, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 Fluorouracil; Colon cancer; Cytotoxicity; Mismatch repair; Necrosis

Indexed keywords

FLUOROURACIL; PROTEIN MLH1;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; DRUG CYTOTOXICITY; DRUG RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FLUOROURACIL; HCT116 CELLS; HUMANS; L-LACTATE DEHYDROGENASE; NUCLEAR PROTEINS; TRANSFECTION;

EID: 84859217919     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.025     Document Type: Article

References (48)

1. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
2. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
3. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., Chollet P., Llory J.F., Letourneau Y., Coudert B., Bertheaut-Cvitkovic F., Larregain-Fournier D., Le Rol A., Walter S., Adam R., Misset J.L., Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000, 18:136-147.
4. Boyer J., McLean E.G., Aroori S., Wilson P., McCulla A., Carey P.D., Longley D.B., Johnston P.G. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res. 2004, 10:2158-2167.
5. Yang B., Eshleman J.R., Berger N.A., Markowitz S.D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res. 1996, 2:1649-1657.
6. Lohwasser S., Ernst H., Hahn E.G., Gossner L., Ell C. Morphological changes in human colon carcinoma after chemotherapy with 5-fluorouracil - a study in the nude mouse model. Z. Gastroenterol. 1997, 35:319-326.
7. van Triest B., Pinedo H.M., van Hensbergen Y., Smid K., Telleman F., Schoenmakers P.S., van der Wilt C.L., van Laar J.A., Noordhuis P., Jansen G., Peters G.J. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin. Cancer Res. 1999, 5:643-654.
8. Mirjolet J.F., Barberi-Heyob M., Merlin J.L., Marchal S., Etienne M.C., Milano G., Bey P. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br. J. Cancer 1998, 78:62-68.
9. Mirjolet J.F., Didelot C., Barberi-Heyob M., Merlin J.L. G(1)/S but not G(0)/G(1) cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002, 48:6-13.
10. De Angelis P.M., Svendsrud D.H., Kravik K.L., Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol. Cancer 2006, 5:20.
11. Showalter S.L., Showalter T.N., Witkiewicz A., Havens R., Kennedy E.P., Hucl T., Kern S.E., Yeo C.J., Brody J.R. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?. Cancer Biol. Ther. 2008, 7:986-994.
12. Robinson H.M., Jones R., Walker M., Zachos G., Brown R., Cassidy J., Gillespie D.A. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 2006, 25:5359-5369.
13. Xiao Z., Xue J., Semizarov D., Sowin T.J., Rosenberg S.H., Zhang H. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int. J. Cancer 2005, 115:528-538.
14. Xiao Z., Xue J., Sowin T.J., Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol. Cancer Ther. 2006, 5:1935-1943.
15. Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 1990, 48:381-395.
16. Fischer F., Baerenfaller K., Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 2007, 133:1858-1868.
17. Wyatt M.D., Wilson D.M. Participation of DNA repair in the response to 5-fluorouracil. Cell. Mol. Life Sci. 2009, 66:788-799.
18. An Q., Robins P., Lindahl T., Barnes D.E. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res. 2007, 67:940-945.
19. Carethers J.M., Chauhan D.P., Fink D., Nebel S., Bresalier R.S., Howell S.B., Boland C.R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131.
20. Bracht K., Nicholls A.M., Liu Y., Bodmer W.F. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br. J. Cancer 2010, 103:340-346.
21. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349:247-257.
22. Carethers J.M., Smith E.J., Behling C.A., Nguyen L., Tajima A., Doctolero R.T., Cabrera B.L., Goel A., Arnold C.A., Miyai K., Boland C.R. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004, 126:394-401.
23. Jover R., Zapater P., Castells A., Llor X., Andreu M., Cubiella J., Pinol V., Xicola R.M., Bujanda L., Rene J.M., Clofent J., Bessa X., Morillas J.D., Nicolas-Perez D., Paya A., Alenda C. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006, 55:848-855.
24. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J.F., Sinicrope F., Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010, 28:3219-3226.
25. Benatti P., Gafa R., Barana D., Marino M., Scarselli A., Pedroni M., Maestri I., Guerzoni L., Roncucci L., Menigatti M., Roncari B., Maffei S., Rossi G., Ponti G., Santini A., Losi L., Di Gregorio C., Oliani C., Ponz de Leon M., Lanza G. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 2005, 11:8332-8340.
26. Lamberti C., Lundin S., Bogdanow M., Pagenstecher C., Friedrichs N., Buttner R., Sauerbruch T. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int. J. Colorectal. Dis. 2007, 22:145-152.
27. Kim G.P., Colangelo L.H., Wieand H.S., Paik S., Kirsch I.R., Wolmark N., Allegra C.J. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 2007, 25:767-772.
28. Elsaleh H., Powell B., Soontrapornchai P., Joseph D., Goria F., Spry N., Iacopetta B. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000, 58:52-59.
29. Elsaleh H., Powell B., McCaul K., Grieu F., Grant R., Joseph D., Iacopetta B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 2001, 7:1343-1349.
30. Liang J.T., Huang K.C., Lai H.S., Lee P.H., Cheng Y.M., Hsu H.C., Cheng A.L., Hsu C.H., Yeh K.H., Wang S.M., Tang C., Chang K.J. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int. J. Cancer 2002, 101:519-525.
31. Sinicrope F.A., Foster N.R., Thibodeau S.N., Marsoni S., Monges G., Labianca R., Yothers G., Allegra C., Moore M.J., Gallinger S., Sargent D.J. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl. Cancer Inst. 2011, 103:863-875.
32. Bhonde M.R., Hanski M.L., Stehr J., Jebautzke B., Peiro-Jordan R., Fechner H., Yokoyama K.K., Lin W.C., Zeitz M.M., Hanski C. Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38. Int. J. Cancer 2009.
33. Koi M., Umar A., Chauhan D.P., Cherian S.P., Carethers J.M., Kunkel T.A., Boland C.R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994, 54:4308-4312.
34. Sato S., Fujita N., Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002, 21:1727-1738.
35. Meyers M., Wagner M.W., Hwang H.S., Kinsella T.J., Boothman D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001, 61:5193-5201.
36. Poorter R.L., Peters G.J., Bakker P.J., Taat C.W., Biermans-van Leeuwe D.M., Codacci-Pisanelli G., Noordhuis P., Oosting J., Veenhof C.H. Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: relationship between plasma concentrations and clinical parameters. Eur. J. Cancer 1995, 31A:1465-1470.
37. Zheng J.F., Wang H.D. 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. World J. Gastroenterol. 2005, 11:3944-3947.
38. Gunasekar P., Li L., Prabhakaran K., Eybl V., Borowitz J.L., Isom G.E. Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells. Toxicol. Sci. 2001, 64:83-89.
39. Moubarak R.S., Yuste V.J., Artus C., Bouharrour A., Greer P.A., Menissier-de Murcia J., Susin S.A. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Mol. Cell Biol. 2007, 27:4844-4862.
40. Galluzzi L., Kepp O., Kroemer G. RIP kinases initiate programmed necrosis. J. Mol. Cell. Biol. 2009, 1:8-10.
41. Bras-Goncalves R.A., Pocard M., Formento J.L., Poirson-Bichat F., De Pinieux G., Pandrea I., Arvelo F., Ronco G., Villa P., Coquelle A., Milano G., Lesuffleur T., Dutrillaux B., Poupon M.F. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 2001, 120:874-888.
42. Guerriero J.L., Ditsworth D., Fan Y., Zhao F., Crawford H.C., Zong W.X. Chemotherapy induces tumor clearance independent of apoptosis. Cancer Res. 2008, 68:9595-9600.
43. Aleskandarany M.A., Green A.R., Rakha E.A., Mohammed R.A., Elsheikh S.E., Powe D.G., Paish E.C., Macmillan R.D., Chan S., Ahmed S.I., Ellis I.O. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int. J. Cancer 2010, 126:1761-1769.
44. Garrity M.M., Burgart L.J., Mahoney M.R., Windschitl H.E., Salim M., Wiesenfeld M., Krook J.E., Michalak J.C., Goldberg R.M., O'Connell M.J., Furth A.F., Sargent D.J., Murphy L.M., Hill E., Riehle D.L., Meyers C.H., Witzig T.E. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2004, 22:1572-1582.
45. Sinicrope F.A., Rego R.L., Garrity-Park M.M., Foster N.R., Sargent D.J., Goldberg R.M., Wiesenfeld M., Witzig T.E., Thibodeau S.N., Burgart L.J. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int. J. Cancer 2007, 120:1232-1238.
46. Robinson B.W., Im M.M., Ljungman M., Praz F., Shewach D.S. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res. 2003, 63:6935-6941.
47. Frouin I., Prosperi E., Denegri M., Negri C., Donzelli M., Rossi L., Riva F., Stefanini M., Scovassi A.I. Different effects of methotrexate on DNA mismatch repair proficient and deficient cells. Eur. J. Cancer 2001, 37:1173-1180.
48. Karran P. DNA damage, DNA repair and therapy-related cancer. Br. Med. Bull. 2006, 79-80:153-170.